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 To identify accessible and permissive human cell types for efficient derivation of induced pluripotent stem cells 
(iPSCs), we investigated epigenetic and gene expression signatures of multiple postnatal cell types such as fibroblasts 
and blood cells. Our analysis suggested that newborn cord blood (CB) and adult peripheral blood (PB) mononuclear 
cells (MNCs) display unique signatures that are closer to iPSCs and human embryonic stem cells (ESCs) than age-
matched fibroblasts to iPSCs/ESCs, thus making blood MNCs an attractive cell choice for the generation of integra-
tion-free iPSCs. Using an improved EBNA1/OriP plasmid expressing 5 reprogramming factors, we demonstrated 
highly efficient reprogramming of briefly cultured blood MNCs. Within 14 days of one-time transfection by one plas-
mid, up to 1000 iPSC-like colonies per 2 million transfected CB MNCs were generated. The efficiency of deriving iP-
SCs from adult PB MNCs was approximately 50-fold lower, but could be enhanced by inclusion of a second EBNA1/
OriP plasmid for transient expression of additional genes such as SV40 T antigen. The duration of obtaining bona 
fide iPSC colonies from adult PB MNCs was reduced to half (~14 days) as compared to adult fibroblastic cells (28-
30 days). More than 9 human iPSC lines derived from PB or CB blood cells are extensively characterized, including 
those from PB MNCs of an adult patient with sickle cell disease. They lack V(D)J DNA rearrangements and vector 
DNA after expansion for 10-12 passages. This facile method of generating integration-free human iPSCs from blood 
MNCs will accelerate their use in both research and future clinical applications.
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Introduction
Human iPSCs that morphologically and functionally 
resemble human embryonic stem cells (ESCs) have been 
generated from many somatic cell types by viral vectors 
expressing defined reprogramming factors since 2007. 
Generation of human iPSCs from blood MNCs offers 
several advantages over other cell types
 [1]. It is more 
convenient and less invasive to obtain PB than dermal 
fibroblasts and keratinocytes, in which several weeks 
are required to establish a primary cell culture from skin 
biopsy. We and others have successfully generated iP-
SCs from human immature MNCs expressing CD34 or 
CD133 markers isolated from umbilical CB, adult PB 
and bone marrow (BM), after cultures of 2-4 days and 
gene transduction by the standard retroviral vectors ex-
pressing 4 or fewer reprogramming genes
 [2-4]. The pu-
rified CD34-expressing (CD34+) and CD133-expressing 
(CD133+, nearly all CD34+) cells from blood or BM (≤ 
2% of total MNCs) are enriched for human hematopoi-
etic stem cells (HSCs). Subsequently, 5 groups used viral www.cell-research.com | Cell Research
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vectors and generated human iPSCs from un-fractionated 
MNCs, after longer cell culture to activate a sub-popu-
lation into a proliferating state [5-9]. Since T cells are 
most abundant in PB MNCs, and can be easily expanded 
and infected by viral vectors under these culture condi-
tions, it is not surprising that all or the vast majority of 
the derived iPSCs in each of the 5 studies contain so-
matic V(D)J DNA rearrangements at the T cell receptor 
(TCR) loci. It is unclear, however, whether the preexist-
ing genomic rearrangements in human T cell-derived 
iPSCs will affect iPSC differentiation to T and non-T cell 
lineages
 [1, 10], and whether T cell-derived iPSCs may 
form T cell lymphomas at an unexpectedly high rate as 
observed with reprogrammed mouse T cells [11]. Thus, 
methods of iPSC derivation without altering the genome 
are preferred, ideally by a virus-free approach. 
Recently, several virus-free and integration-free meth-
ods were reported, which generated mouse and human 
iPSCs by using purified proteins or mRNAs, as well as 
plasmids [12-18]. However, most of these published 
studies using proteins or mRNAs needed serial delivery 
(up to 17-21 times) of multiple reprogramming mol-
ecules to targeted adherent cells. Two of these studies 
used plasmid-based episomal vectors to successfully 
reprogram human fetal neural progenitor cells and neo-
natal fibroblasts, generating integration-free iPSC lines 
[17-18]. This is based on a well-established technology 
that inclusion of the EBNA1 gene and the OriP DNA 
sequence from the Epstein-Barr virus (EBV) enables a 
plasmid, after one-time DNA transfection, to replicate 
extra-chromosomally in many types of primate cells as a 
circular episome [19]. However, the reported efficiency 
of reprogramming postnatal cells was very low (~3-6 
per 10
6 neonatal human fibroblasts), even when the best 
combination of 3 EBNA1/OriP plasmids expressing 7 
genes was used in DNA transfection
 [17]. For cell thera-
py development and disease modeling, it is necessary to 
develop more efficient methods to generate integration-
free and virus-free human iPSCs from adult somatic cells 
that tend to be more refractory to reprogramming than 
fetal/neonatal cells. To this end, we constructed improved 
EBNA1/OriP episomal vectors for efficient reprogram-
ming of adult and neonatal somatic cells. In addition, we 
sought human postnatal cell types that are easily acces-
sible, and more importantly, amenable to producing high-
quality iPSCs efficiently. 
Results
Unique epigenetic and gene expression signatures of hu-
man blood cells 
In this study, we analyzed global promoter DNA meth-
ylation in human CD34+ cells from CB, adult PB and 
BM, which are enriched for HSCs and appear more ef-
ficient in deriving iPSCs after improvement of retroviral 
delivery of standard reprogramming factors
 [2-4]. Their 
signatures were compared to cultured adult BM-derived 
MSCs and other age-matched non-hematopoietic cells. 
We also included 11 human ESC samples to establish a 
baseline and 20 iPSC lines derived from the above somatic 
cell types, including 15 lines we derived previously by 
using integrating vectors
 [2, 20] and 5 iPSC lines derived 
by using episomal vectors in this study. To assess global 
DNA methylation, we performed genome-wide analysis 
using Illumina’s Infinium Methylation27 platform con-
taining 27 578 informative CpG sites near the promoter 
region, in which hypermethylation often correlates with 
repression of gene expression. A dendrogram plot using 
Euclidean distances revealed that the 20 validated iPSC 
lines derived from various somatic cell sources are high-
ly similar to ESCs, but distinct from their parental cells 
(Figure 1). The cultured human blood (CD34+) cells are 
distinct from cultured endothelial cells (also CD34+) or 
MSCs/fibroblasts (CD34–). We also found that cultured 
blood (CD34+) cells cluster closer with the ESC/iPSC 
group than the non-hematopoietic cells (Figure 1). A 
similar clustering is also observed when using Pearson 
correlations to determine the distance metric (data not 
shown). 
We next did a K-means clustering analysis of the same 
data (Figure 2A). The levels of promoter DNA methy-
lation at 26 424 autosomal loci in postnatal blood/BM 
CD34+ hematopoietic cells and adult BM-derived MSCs 
were analyzed. Four distinct clusters emerged, based on 
relative levels of promoter DNA methylation in somatic 
cells as compared to the 11 ESCs (Figure 2A). Cluster #2 
(high in somatic cells but low in ESCs) and cluster #3 (low 
in somatic cells and high in ESCs) contain loci showing 
different promoter DNA methylation levels between so-
matic cells and ESCs. While 15.4% of loci in MSCs are 
different from ESCs, only 10.8% of loci in CD34+ cells 
are different from ESCs, suggesting that hematopoietic 
CD34+ cells are closer to ESCs (and iPSCs, not shown) 
by this global analysis. In cluster #2, there are 234 loci 
(~1%) that are hypermethylated in cultured MSCs but 
hypomethylated in blood CD34+ cells and ESCs/iPSCs 
(Figure 2B and Supplementary information, Table S1). 
We confirmed the high-level expression of two differen-
tially hypomethylated genes, namely HMGA1 and BCL2, 
by quantitative RT-PCR in cultured CD34+ cells com-
pared to MSCs derived from the same BM donor (Figure 
2C). HMGA1 expression is high in undifferentiated hu-
man ESCs/iPSCs (and low in differentiated progeny) and 
in human CD34+ hematopoietic cells (and low in CD34– Human iPS cells derived from blood cells by a plasmid
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Figure 1 Global epigenetic signatures and relatedness of human ESC lines, iPSC lines and their parental somatic cells. A 
dendrogram plot using Euclidean distances and average linkage based on DNA methylation at 26 424 autosomal loci in the 
Infinium Methylation27 platform, to analyze promoter DNA methylation genome-wide. 11 hESCs (passages 30-80) and 20 
iPSCs derived from various somatic cell types (passage 5-15) that have a normal karyotype and validated pluripotency were 
analyzed. Parental cell types used for reprogramming include cultured CD34+ cells from cord blood (CB), adult peripheral 
blood (PB) and adult bone marrow (BM), CB and PB mononuclear cells (MNCs) before (D0) and after culture (D8), 4 types 
of adult BM stromal cells (MSC-BM, MSCs and BASC) and IMR90 fetal fibroblasts, neonatal cord-derived endothelial cells 
(CD34+) such as HUVEC and CB-derived endothelial progenitor cells (CB-EPCs). The clustering confirms that the 20 validat-
ed iPSC lines derived from various somatic cell sources are highly similar to ESCs, but distinct from their parental cells. DNA 
methylation patterns in human blood cells are more similar to ESC/iPSC group as compared to age-matched non-hematopoi-
etic cells. Based on a two-sample t-test with unequal variances, we confirmed that the different mean distance corresponding 
to the indicated nodes a and b is statistically significant (P < 0.01). 
cells)
 [21-22]. BCL2 is highly expressed in CD34+ cells 
and mouse HSCs, and known to be critical for blocking 
apoptosis in HSCs as well as B cells
 [23]. Interestingly, 
cultured BM CD34+ cells also express much higher 
levels of KLF4 and c-MYC than MSCs (Figure 2C), as 
found previously in CB CD133+/CD34+ cells
 [4]. Thus, 
our data provide a rationale why hematopoietic CD34+ 
cells from CB and adult sources have a higher repro-
gramming efficiency than fibroblastic cells, as observed 
previously when retroviral vectors were used
 [2, 4, 20]. 
Reprogramming human CB CD34+ cells by episomal 
vectors
We next tested a novel set of EBNA1/OriP plasmids 
we constructed for reprogramming cultured CB CD34+ 
cells, which have the most favorable epigenetic/gene 
expression signatures and proliferative capacity as 
compared to adult CD34+ cells or fibroblasts/MSCs. 
In the first EBNA1/OriP plasmid (called pEB-C5), 5 
reprogramming factors (OCT4, SOX2, KLF4, c-MYC 
and LIN28) are expressed as a single poly-cistronic unit 
(Supplementary information, Figures S1 and S2). In the 
second set of EBNA1/OriP plasmids, SV40 Large T anti-
gen (Tg), NANOG or a small hairpin RNA targeting p53 
(p53shRNA) is individually expressed. In the first set of 
3 experiments (Supplementary information, Figure S3), 
the pEB-C5 and pEB-Tg plasmids were used in compari-
son with the Thomson/Yu combination #6 containing 3 www.cell-research.com | Cell Research
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Figure 2 Global epigenetic signature changes and gene expression patterns of human CD34+ hematopoietic cells and mes-
enchymal stem cells (MSCs). (A) K-means clustering analysis using the same promoter DNA methylation data as in Figure 1. 
To simplify presentation, we omitted iPSCs since they are highly similar to ESCs (11 lines/batches) that established a base-
line. Two different samples of CD34+ cells from cord blood (CB), peripheral blood (PB) and bone marrow (BM) were used, 
together with 3 adult MSCs 3 samples. The level of promoter DNA methylation (from 0 to 1) of various loci (either within a 
CpG island or not) in postnatal somatic cells and in 11 ESC lines is analyzed. Four distinct clusters emerged: 1) high in both; 2) 
high in at least one type of somatic cells but low in ESCs; 3) low in somatic cells but high in ESCs; and 4) low in both somatic 
cells and ESCs. The numbers of loci in each cluster common in 3 MSCs or CD34+ cells are listed in the insert table. Clusters 
#2 and #3 consists of loci that are methylated differently from ESCs. Combining the two clusters, 15.4% of loci in MSCs are 
different from ESCs and only 10.8% of loci in CD34+ cells are different from ESCs. A list of cluster #2 genes that are hypom-
ethylated in CD34+ cells and in ESC/iPSCs, but hypermethylated in MSCs is shown in Supplementary information, Table S1. (B) 
DNA methylation levels (mean +/– SEM, n ≥ 3) of two such genes are HMGA1 and BCL2 in multiple samples of BM MSCs, 
CD34+ cells, iPSCs and ESCs are plotted, together with the endogenous levels of the 4 reprogramming genes (OCT4 [also 
known as POU5F1], SOX2, KLF4, and c-MYC). Levels at the CD34 gene loci are also plotted as a control. (C) The high lev-
els of HMGA1 and BCL2 mRNA expression in cultured BM CD34+ cells (versus MSCs from the same donor) correlate with 
the lack of repressive hypermethylation marks. The levels of KLF4 and c-MYC expression are also very high in the cultured 
CD34+ cells used for reprogramming. 
plasmids [17]. After expansion (~5-fold) with cytokines 
for 4 days, CB CD34+ cells were transfected once and 
then cultured on MEF feeders following the standard pro-
tocol for deriving human iPSCs
 [2, 20] (Figure 3A and 
Supplementary information, Figure S3A). Previous stud-
ies showed that the acquisition of cell surface expression 
of TRA-1-60/TRA-1-81 is a reliable marker for monitor-
ing full reprogramming of human somatic cells [20, 24-Human iPS cells derived from blood cells by a plasmid
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25]. We performed live staining of whole cultures at day 
14 and numerated both TRA-1-60 positive and negative 
colonies (Supplementary information, Figure S3B-S3E). 
Our 2-plasmid combination generated similar numbers 
of TRA-1-60+ colonies (Supplementary information, 
Figure S2D), but their percentages among total colonies 
were much higher than combination #6 (Supplementary 
information, Figure S3E). We also observed that sodium 
butyrate (NaB), a nutritional supplement and HDAC 
inhibitor that stimulates reprogramming of human fibro-
blastic cells
 [20], also consistently enhanced the number 
(and percentages) of TRA-1-60+ colonies genetated by 
either vector combination (Supplementary information, 
Figure S3D-S3E). 
In the second set of experiments, we tested whether 
we could replace Tg by either NANOG or p53shRNA 
(which inhibits p53 as by Tg expression), or omit Tg 
completely (Figure 3B-3C). The stimulatory effect of 
CB CD34+ cell reprogramming by the second vector 
over pEB-C5 alone was the greatest for Tg followed 
by p53shRNA, and minimal for NANOG. The pEB-C5 
plasmid alone was sufficient to generate ~50 TRA-1-
60+ colonies from 10
6 nucleofected cells (expanded from 
~0.2 × 10
6 original CD34+ cells) without NaB (Figure 
Figure 3 Reprogramming of human hematopoietic CD34+ cells from cord blood by 1-2 episomal vectors. (A) A diagram of 
procedure for human iPSC generation from blood cells. Purified CD34+ cells were cultured with cytokines for 4 days, and 
then nucleofected one-time by 1-2 plasmids at day 0. Transfected cells were cultured for 2 more days before transferring onto 
6 wells coated with MEF feeder cells. At day 3, the ESC culture medium was used +/– sodium butyrate (NaB). After day 9, the 
MEF-derived conditioned medium (CM) was used to substitute plain ESC medium. At day 14, cultures were stained live with 
the TRA-1-60 antibody. (B) Reprogramming efficiency of cord blood (CB) CD34+ cells by various combinations of EBNA1/
OriP epiosmal vectors, either pEB-C5 (C5) + pEB-Tg (Tg), C5 + pEB-p53shRNA, C5 + pEB-NANOG or C5 alone. The ef-
ficiency is measured at day 14 as numbers of TRA-1-60+, ESC-like colonies per 10
6 nucleofected cells (B). The percentages 
of TRA-1-60+ colonies among the total colonies are also plotted (C). Data are plotted as mean +/– SEM (n = 3). Discrete 
TRA-1-60+ colonies with the best ESC-like morphology were selectively picked after counting. (D) Phenotypes of expanded 
iPSC clone C7 derived from CB CD34+ cells by the single C5 vector. Scale bar: 100 µm throughout. (E) The C7 iPSCs dis-
play normal pluripotency as assayed by embryoid body formation and in vitro differentiation. Various cell types derived from 
all the 3 embryonic germ layers were found, based on positive staining of beta-3-tubulin (ectoderm), smooth muscle actin 
(mesoderm) and alpha-fetal protein or AFP (endoderm). Cell nuclei were counterstained by DAPI (blue). (F) In vivo pluripo-
tency of C7 assayed by teratoma formation. The presence of various cell types derived from all the 3 embryonic germ layers 
(ectoderm, mesoderm and endoderm) are shown in representative images of H & E stained sections. www.cell-research.com | Cell Research
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3B). In the presence of NaB during the reprogramming 
(day 3-14), ~160 TRA-1-60+ colonies were generated (> 
3-fold), accounting for ~50% of the total colonies formed 
(Figure 3C).
After TRA-1-60 live staining, we picked individual 
ESC-like colonies derived by transfection with either 
pEB-C5 alone (C), pEB-C5 + pEB-Tg (CT) or CT in 
the presence of NaB (CTN). We examined at least two 
CB-derived clones from each category by standard as-
says. Undifferentiated phenotypes of one representative 
clone, C7, are shown in Figure 3D, and additional clones 
CT5 and CTN4 are shown in Supplementary informa-
tion, Figure S4. We found that 5 of 6 clones derived with 
pEB-C5 + pEB-Tg vectors have a normal karyotype 
(CT5 and CTN4 are shown in Supplementary informa-
tion, Figure S4D-S4E). To further analyze iPSCs derived 
with transient expression of Tg, we used genome-wide 
SNP analysis to examine the similarity of the CT5 and 
CTN4 genome to that of primary CB CD34- cells from 
the same CB donor. The genome-wide data (covering > 
10
6 SNPs) indicate that CT5 and CTN4 iPSCs are essen-
tially identical to CD34- cells of the CB donor and that 
reprogramming by the episomal vectors did not cause 
any detectable alterations in the genome (see Methods). 
Equally important, CT5 and CTN4 iPSCs are pluripotent 
as validated by both in vitro and in vivo differentiation 
assays (Supplementary information, Figure S4B-S4C). 
Similarly, the iPSC clones derived by the single C5 vec-
tor from the same donor (CN1) and a different donor (C7) 
are also pluripotent. The pluripotency and karyotyping 
data of the C7 iPSC line are shown in Figure 3E-3F and 
Figure 4D. 
Reprogramming adult hematopoietic CD34+ cells by 1-2 
episomal vectors
We next used this approach to derive iPSCs from hu-
man adult PB or BM CD34+ cells by 1 or 2 EBNA1/OriP 
plasmids (Figure 4). After 4 days of culture and expan-
sion, 10
6 primed cells were nucleofected by the same sets 
of plasmids. The ESC-like TRA-1-60+ colonies emerged 
at day 9-11, about 3-4 days later than those from CB 
CD34+ cells. We found the efficiency of reprogramming 
adult CD34+ cells was ~50-fold lower than CB CD34+ 
cells (per 10
6 cells transfected by the same vector sets), 
although sufficient numbers of iPSC colonies formed 
(Figure 4A-4B). Adding a second EBNA1/OriP vector 
expressing Tg or shRNA targeting p53 increased the ef-
ficiency by ~5-fold. Human iPSC clones derived from 
adult CD34+ cells by the single pEB-C5 vector were 
picked, expanded and characterized as before. One clone 
from PB CD34+ cells (PC1) and one from BM CD34+ 
cells (BC1) were further characterized after 5-12 pas-
sages. Both iPSCs show undifferentiated phenotypes 
(Figure 4C) and have normal karyotypes as C7 iPSCs 
derived from CB CD34+ cells (Figure 4D). They are also 
pluripotent by in vitro (Figure 4E) and in vivo (Figure 
4F) differentiation assays, similar to C7 iPSCs shown 
in Figure 3. We also examined the presence of the vec-
tor DNA in these 3 iPSCs at various stages (Figure 4G). 
In general, a trace amount of vector DNA (< 0.2 copies 
per cell) could be detected after reprogramming (lasting 
14 days) and expansion for 9 passages (~50 days), but 
they became undetectable in most cases by passage 10-
12 (Figure 4G and Supplementary information, Figure 
S4G). Our data are consistent with previous publications 
showing that the EBNA1/OriP episomal DNA in human 
fetal or neonatal cell-derived iPSCs is spontaneously and 
gradually lost after reprogramming [17-18]. This is likely 
due to the silencing of EBNA1 gene expression and/or 
loss of OriP DNA functions in iPSCs, resulting from dif-
ferent DNA methylation and other epigenetic regulations 
from those in somatic cells. We also performed DNA fin-
gerprinting on these iPSC lines derived by a single non-
integrating vector and confirmed their authentic origins 
(Supplementary information, Figure S5).
Culture and activation of un-fractionated blood MNCs 
for reprogramming
Next, we attempted to reprogram un-fractionated 
blood MNCs (without CD34 cell purification) by the im-
proved episomal vectors. Uncultured or cultured MNCs 
under the CD34+ cell culture condition did not survive 
well before or after nucleofection, resulting in zero iPSC 
colonies per 5 million MNCs. We tested various culture 
conditions that would stimulate myeloid-erythroid prolif-
eration from MNCs, and avoided the standard protocols 
expanding T and/or B cells that contain V(D)J DNA re-
arrangements (and thus an altered genome). We chose a 
condition that stimulates erythroblast proliferation
 [26] 
for the following 4 reasons. 1) We observed net gains 
of cell numbers after culture: 2.5-fold by day 8 for CB 
MNCs and 1.5-fold by day 8-9 for PB MNCs, despite a 
reduction in the first 2-4 days (Supplementary informa-
tion, Figure S6A). 2) The expanded cells contained very 
few T or B cells compared to input MNCs (Supplemen-
tary information, Figure S6B-S6C). Nearly all the ex-
panded cells expressed an erythroblast marker CD36 (not 
shown), and many expressed CD71
high/CD235a
+ erythroid 
phenotypes. They also showed erythroblast morphology 
at day 8-9 (Supplementary information, Figure S7A), 
and were enriched for colony-forming erythroid progeni-
tor cells (Supplementary information, Figure S7B). The 
data suggest that the resulting cells after expansion are 
enriched for highly proliferative erythroblasts as previ-Human iPS cells derived from blood cells by a plasmid
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Figure 4 Reprogramming of human adult hematopoietic CD34+ cells. Reprogramming efficiency of adult peripheral blood (PB, 
A) or bone marrow (BM, B) CD34+ cells by various plasmid combinations in the presence of NaB, as conducted in Figure 3. 
Numbers of TRA-1-60+, hESC-like colonies were numerated (mean +/– SEM) at day 14 after one-time nucleofection of 10
6 
expanded cells. (C) Phenotypes of expanded iPSC clone BC1 derived from BM CD34+ cells by the single C5 vector. Scale 
bar: 100 µm throughout. (D) Normal karyotypes of iPSC lines derived by the single C5 vectors from 3 types of human CD34+ 
cells. (E) The BC1 iPSCs display normal pluripotency as assayed by embryoid body (EB) formation and in vitro differentia-
tion. Various cell types derived from ectoderm (beta-3-tubulin), mesoderm (smooth muscle actin) and endoderm (alpha-fetal 
protein or AFP) were found. (F) In vivo pluripotency of BC1 assayed by teratoma formation. Both low (10×) and high (20×) 
magnification images of multiple H & E stained sections are shown. Various cell types such as neural rosettes (ectoderm), 
bone (mesoderm) and glandular structures (endoderm) are found. (G) PCR-based detection of vector sequence (EBNA1) in 3 
iPSCs derived from human CD34+ by the single C5 vector. The single-copy cellular sequence beta-actin is used as a quality 
control for isolated genomic DNA. Total DNA isolated from the cells before (naïve) and after nucleofection (day 2) was used 
as negative and positive controls for vector DNA. The pEB-Tg plasmid diluted in amounts equivalent to 1, 0.2 or 0.04 copies 
per genome of cellular DNA is used as a control for detection of the EBNA1 viral DNA sequence.
ously reported
 [26]. 3). The expanded cells from adult 
PB MNCs resembled neonatal cells found in CB cells. 
Surprisingly the levels of fetal/neonatal hemoglobin 
(HBG, gamma-globin) gene expression were greatly (> 
8 000-fold) increased in expanded PB MNCs, and more 
cultured cells (> 70%) expressed HBG (gamma-globin) 
proteins as compared to uncultured PB MNCs (Supple-
mentary information, Figure S8). 4). The culture condi-
tion also elevated the expression of genes associated with 
pluripotency or reprogramming enhancement such as 
HMGA1 and c-MYC (Supplementary information, Figure 
S9). 
Reprogramming un-fractionated blood MNCs by epi-
somal vectors after stimulation by cell culture
We further devised a condition to efficiently transfect 
expanded cells with favorable profiles. Two million cells 
were transfected one-time by nucleofection with the same 
1-2 EBNA1/OriP episomal vectors, and followed by an 
identical reprogramming protocol as before (Figure 3A). www.cell-research.com | Cell Research
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The cultured CB MNCs after 8-day culture can generate 
TRA-1-60+ iPSC-like colonies very efficiently (Figure 
5A). Although variations of different CB MNC prepara-
tions existed, the overall reprogramming efficiency is 
very high: 930 and 320 TRA-1-60+ colonies formed by 
day 14 per 2 × 10
6 transfected MNCs by the single pEB-
C5 episomal vector in the presence of NaB. The stimula-
tory effect of Tg or NaB is minimal for the cultured CB 
MNCs (Figure 5A). The generation of iPSCs by the 1-2 
EBNA1/OriP episomal vectors was also achieved with 
the cultured PB MNCs including those from an adult 
sickle cell disease patient (SCD003), although the effi-
ciency is much lower than that of CB MNCs (Figure 5B 
and Supplementary information, Figure S10). The pEB-
C5 vector alone is sufficient to generate 3.2 iPSCs at day 
14 after transfection of 2 × 10
6 cultured MNCs that can 
be easily obtained from ~10
6 MNCs isolated from ≤ 1 
ml volume of PB. Similar to adult PB CD34+ cells, PB 
Figure 5 Human iPSC derived from adult peripheral blood (PB) and cord blood (CB) mononuclear cells (MNCs) by a single 
EBNA1/OriP plasmid. (A) Reprogramming efficiency of CB MNCs. Two different CB MNCs, frozen 1.5 months before (GB/
CB) and 13 years before (AC/CB), were cultured for 8 days. 2 × 10
6 cultured and primed cells were nucleofected by 1-3 
EBNA1/OriP plasmids as indicated. C5: pEB-C5; Tg: pEB-Tg; Combo 6: the Thomson/Yu combination #6 (3 plasmids). The 
reprogramming proceeded as with CD34+ cells (Figure 3A), with or without sodium butyrate (NaB). Numbers of TRA-1-60+ 
colonies (on day 14) per 2 × 10
6 nucleofected cells are plotted as mean +/– SEM, n = 3. (B) PB MNCs (from donor SCD003) 
were similarly reprogrammed by the same approach in the presence of NaB (day 3-14), after an initial cell culture and stimu-
lation for 8-9 days. (C) Representative images of undifferentiated phenotypes of an iPSC clone (NC1, passage 5) generated 
from SCD003 PB MNC-derived erythroblasts (SPE) by the pEB-C5 (C5) vector alone + NaB. Scale bar: 100 µm throughout. 
(D) Blood MNC-derived iPSCs such as NC1 display normal pluripotency as assayed by embryoid body (EB) formation and 
in vitro differentiation. Various cell types derived from ectoderm (beta-3-tubulin), mesoderm (smooth muscle actin) and endo-
derm (alpha-fetal protein or AFP) were found. (E) In vivo pluripotency of NC1 assayed by teratoma formation. Both low (10×) 
and high (20×) magnification images of multiple H & E stained sections are shown. Various cell types such as neural rosettes 
(ectoderm), bone (mesoderm) and glandular tissues (endoderm, yellow arrow) were found. (F) Normal karyotypes of 2 iPSC 
lines (NC1 and TNC1) derived by a single plasmid (C5) or two plasmids (C5+Tg). (G) Lack of vector DNA in expanded iPSCs 
(clones NC1, TNC1, TNC2 and TNC3) after 10-12 passages, as analyzed in Figure 4G. (H) Selected iPSCs (passages 11-
12) were also analyzed by a different pair of PCR primers to detect vector DNA at the region encoding reprogramming trans-
genes. Lack of vector DNA in the iPSCs by Southern blot analysis is shown in Supplementary information, Figure S11.  Human iPS cells derived from blood cells by a plasmid
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MNC reprogramming is more dependent than CB MNCs 
on NaB stimulation. Adding pEB-Tg further increased 
the efficiency by ~4-fold, resulting in 14 iPSCs per 2 × 
10
6 cultured MNCs. Thus, the efficiency is adequate for 
nearly all applications involving PB, and is even higher 
with CB MNCs (Figure 5A). 
We further characterized the iPSC lines derived from 
cultured adult PB MNCs (called SPE for Sickle PB 
Erythroblast). Four expanded and further character-
ized SPE iPSC lines derived by pEB-C5 alone (NC1) 
or two vectors including pEB-Tg (TNCx, x = 1, 2, or 3) 
show undifferentiated phenotypes (Figure 5C). They are 
pluripotent as confirmed by both in vitro and in vivo dif-
ferentiation assays (Figure 5D-5E), and normal in karyo-
type (Figure 5F). Four characterized iPSC clones (NC1, 
TNC1, 2 and 3) were also analyzed by PCR to detect the 
presence of vector DNA (such as EBNA1) in expanded 
iPSCs at various passages. We again found that the plas-
mid DNA is undetectable after 10-12 passages of iPSC 
expansion (Figure 5G and 5H). Similar results were 
found when PCR detection for vector DNA from a differ-
ent region was conducted. We also conducted Southern 
blot analysis that is capable of detecting a single copy of 
vector DNA (Supplementary information, Figure S11). 
The southern blot did not detect the vector DNA either 
as episomes or anywhere in the genome of NC1, TNC1, 
BC1 and C7 iPSCs we analyzed. We also examined if 
the iPSC lines we derived from cultured PB MNCs could 
be from T or B lymphocytes (Supplementary informa-
tion, Figure S12). Using 7 sets of probes for detecting 
rearranged TCR and immunoglobin (IGH) loci, we did 
not find any evidence of somatic V(D)J rearrangements 
in the 6 iPSC lines. Table 1 summarizes the characteriza-
tions of 10 most analyzed iPSC lines we derived from 
human blood cells by transient transfection of 1-2 epi-
somal vectors.  
Discussions
We describe in this report an efficient method for gen-
erating human iPSCs with an intact genome by using a 
single episomal vector to transfect briefly-cultured adult 
PB or CB MNCs. Transient expression of a second vec-
tor (pEB-Tg) further increased reprogramming efficien-
cies of adult PB CD34+ and MNCs by 4-fold, although 
its stimulatory activity is much less on CB cells that have 
a much higher reprogramming efficiency. Tg stimula-
tion on reprogramming was observed by several groups 
using different vectors and somatic cell types [17, 27]. 
Transient expression of Tg by episomal vectors did not 
necessarily alter karyotypes of the derived iPSCs ([17] 
and this study), or global epigenetic signatures as shown 
in Figure 1. Transient p53 inhibition by shRNA expres-
sion from an episomal vector also enhanced reprogram-
ming efficiency as previously observed in studies using 
genome-integrating viral vectors [28, 29], although its 
stimulatory effect on PB cell reprogramming is less 
than Tg over-expression. Interestingly, we noticed that 
all 5 of the iPSC lines derived from blood cells by non-
integrating vectors we analyzed so far clustered together 
(and close to a group of hESC lines), based on promoter 
DNA methylation signatures. They appear distinct from 
other iPSCs derived by integrating vectors from either 
blood CD34+ cells or MSCs/fibroblasts (Figure 1). A 
recent study found that mouse blood cell-derived iPSCs 
more closely resemble ESCs epigenetically and function-
ally than those derived from fibroblasts
 [30]. Whether the 
virus-free and integration-free human iPSCs we derived 
from blood cells and by the non-integrating vectors are 
superior in quality (closer to the best human ESCs) than 
previous iPSC lines derived by integrating vectors re-
mains to be determined.  
Our EBNA1/OriP episomal vector system offers sev-
eral important advantages over the previous episomal 
vector combinations for reprogramming postnatal human 
cell types [17]. First, the pEB-C5 plasmid (+/– pEB-Tg) 
generated a higher percentage of TRA-1-60+ pre-iPSC 
colonies, especially in the presence of NaB, facilitating 
the efficient isolation of the desired TRA-1-60+ colonies. 
Second, the platform is more flexible if one needs to omit 
or replace Tg with other factors for mechanistic investi-
gations. More importantly, our vector system, together 
with optimized cell culture conditions, allows us to ef-
ficiently generate integration-free human iPSCs from 
blood MNCs isolated from a few milliliters of blood 
after suspension cultures for 8-9 days. When further 
enhancement is needed for other cell types, or patient’s 
blood MNCs that are more refractory to reprogramming 
by the current episomal vectors, we can easily add ad-
ditional reprogramming genes over the 5-6 transgenes 
we used. Since we can deliver multiple (at least 8) genes 
from a single EBNA1/OriP plasmid for simultaneous 
and transient expression, it is no longer critical to reduce 
the numbers of reprogramming factors used. Obviously, 
small numbers of vectors (1-2) are preferred to ensure 
the lack of episomal vector DNA in the reprogrammed 
and expanded iPSC lines. Using PCR (3 sets of specific 
primers) and Southern blot, we did not detect vector 
DNA either as episomes or anywhere in the genome of 
the iPSCs analyzed. More sensitive methods are needed 
to detect residual vector DNA or to eliminate (episomal) 
vector DNA more efficiently than the passive expansion 
and dilution approach we used here.   
Increasing evidence suggests that both DNA repli-Human iPS cells derived from blood cells by a plasmid
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cation-dependent and -independent mechanisms are 
involved in promoting reprogramming, which is funda-
mentally an epigenetic process
 [31]. Our success in gen-
erating iPSCs from un-fractionated human blood MNCs 
depends on a culture condition to obtain a proliferating 
cell population that is neither T nor B cells, before plas-
mid-mediated reprogramming. We also detected that the 
proliferating cells derived from human blood MNCs or 
purified CD34+ cells display a global profile of promoter 
DNA methylation that groups closer to human ESCs/
iPSCs than age-matched non-hematopoietic cells such 
as fibroblastic and endothelial cells. The unique blood 
cell DNA methylation and gene expression signatures 
may contribute to the high efficiency of iPSC derivation 
from blood cells we achieved by using a single episomal 
vector after one-time DNA transfection. Our data further 
substantiate the hypothesis that differences in epigenetic 
profiles among different human adult cell types contrib-
ute to differences in reprogramming efficiencies as well 
as the properties of derived iPSCs, as previously shown 
in the mouse system
 [30]. It is of interest to determine 
if the serial delivery of synthetic mRNAs encoding 4-5 
reprogramming factors or purified proteins could repro-
gram human blood MNCs more efficiently than human 
fibroblasts as reported recently.
The facile method described here that reprograms 
blood cells after minimal culture and using plasmids 
provides several important advantages over other virus-
free and integration-free methods. First, one-time deliv-
ery of 1-2 plasmids that are much easier to produce and 
more stable than proteins or mRNAs makes our method 
more attractive or feasible for generation of clinical-
grade iPSCs under current good manufacture practice 
(cGMP) conditions. Second, the capability to reprogram 
PB MNCs not only provides a readily available source of 
human cells for iPSC derivation
 [1], but also shortens the 
cell culture time required to prepare and prime the tar-
get cells for reprogramming (now < 10 days from blood 
versus ≥ 4 weeks from skin biopsies). Our combined 
method of using MNCs from a few milliliters of blood 
and non-integrating plasmids brings the iPSC derivation 
technology to a new level, and offers greater promise for 
the use of patient iPSCs for disease modeling and future 
clinical applications in regenerative medicine.
Materials and Methods
Approvals of using human ESCs, iPSCs and primary cells 
from anonymous donors
The experimental designs using human ESCs and iPSCs were 
approved by the Institutional Stem Cell Research Oversight 
(ISCRO) committee in the Johns Hopkins University. Use of 
anonymous human samples for laboratory research was approved 
by the Institutional Review Board. 
Constructions of episomal vectors 
All transgenes were cloned into the EBNA1/OriP-based 
pCEP4 episomal vector (Invitrogen). A single EBNA1/OriP vec-
tor expressing five (mouse) cDNAs Oct4, Sox2, Klf4, c-Myc and 
Lin28 that are linked by 2A sequences and under the control of the 
synthetic CAG promoter was constructed in the pCEP4 plasmid 
backbone, analogous to a piggyBac transposon plasmid we previ-
ously used
 [20]. The cDNA for the SV40 large T antigen was PCR 
cloned and inserted into the pCEP4 plasmid backbone as we did 
previously into a lentiviral vector
 [27]. The expression cassette for 
expressing p53-shRNA was obtained by digesting a fragment from 
a pSUPER-based vector, and was inserted into the pCEP4 plasmid. 
See more details in Supplementary information, including Figures 
S1 and S2.
Genome-wide analysis of promoter DNA methylation
The promoter DNA methylation data was generated using the 
Infinium Human DNA Methylation27 BeadArray platform (Illu-
mina, San Diego, California). This platform allows us to interro-
gate DNA methylation of 27 578 informative CpG sites at single-
nucleotide resolution.
Additional Materials and Methods are provided in Supple-
mentary information, Data S1.
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